PUBLISHER: The Business Research Company | PRODUCT CODE: 1951674
PUBLISHER: The Business Research Company | PRODUCT CODE: 1951674
C-X-C chemokine receptor type 2 (CXCR2) is a G protein-coupled receptor mainly expressed on neutrophils and other immune cells. It binds chemokines to direct chemotaxis, guiding immune cells to sites of inflammation or infection. Its primary role is to regulate inflammatory responses and immune cell recruitment, playing a critical part in host defense and pathological inflammation.
The main product types of CXCR2 include antagonists, agonists, inhibitors, and others. Antagonists are drugs that block the receptor's activity, preventing chemokine binding and thereby reducing inflammation and immune cell recruitment. Available drug types include monoclonal antibodies, small molecule inhibitors, peptide-based therapeutics, and gene therapy products. These are administered via various routes, such as intravenous, subcutaneous, oral, and topical. They are applied in a range of areas, including cancer treatment, autoimmune disorders, infectious diseases, and inflammatory diseases, and are used by end users such as hospitals, research institutions, pharmaceutical companies, contract research organizations, and others.
Tariffs have impacted the CXCR2 market by raising the cost of imported biologics, small molecule inhibitors, and research reagents, disrupting supply chains and increasing treatment costs. Segments like monoclonal antibodies, gene therapy products, and peptide-based therapeutics are most affected, particularly in North America, Europe, and Asia-Pacific regions such as China and India. While tariffs pose cost challenges, they have also incentivized local manufacturing, investment in domestic production, and innovation in cost-efficient CXCR2-targeted therapies.
The c-x-c chemokine receptor type 2 market research report is one of a series of new reports from The Business Research Company that provides c-x-c chemokine receptor type 2 market statistics, including c-x-c chemokine receptor type 2 industry global market size, regional shares, competitors with a c-x-c chemokine receptor type 2 market share, detailed c-x-c chemokine receptor type 2 market segments, market trends and opportunities, and any further data you may need to thrive in the c-x-c chemokine receptor type 2 industry. This c-x-c chemokine receptor type 2 market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The c-x-c chemokine receptor type 2 market size has grown rapidly in recent years. It will grow from $1.38 billion in 2025 to $1.55 billion in 2026 at a compound annual growth rate (CAGR) of 11.8%. The growth in the historic period can be attributed to limited understanding of cxcr2 biology, reliance on conventional anti-inflammatory drugs, growing research on chemokine signaling, early-stage monoclonal antibody development, increasing prevalence of inflammatory diseases.
The c-x-c chemokine receptor type 2 market size is expected to see rapid growth in the next few years. It will grow to $2.39 billion in 2030 at a compound annual growth rate (CAGR) of 11.5%. The growth in the forecast period can be attributed to development of novel small molecule and peptide inhibitors, expansion of clinical trials for cxcr2 therapies, rising adoption of personalized and targeted immunotherapies, integration of digital biomarkers and ai-based drug discovery, increasing pharmaceutical investment in oncology and autoimmune markets. Major trends in the forecast period include development of selective cxcr2 inhibitors and dual cxcr1/2 inhibitors, advancements in monoclonal antibody and peptide-based therapeutics, expansion of applications in cancer, autoimmune, and inflammatory diseases, growth in gene therapy and rna-based therapeutics targeting cxcr2, integration of cxcr2 targeted therapies with personalized medicine approaches.
The rising prevalence of inflammatory conditions is expected to drive the growth of the C-X-C chemokine receptor type 2 market in the coming years. Inflammatory conditions are medical disorders caused by the body's immune response, leading to swelling, redness, heat, pain, and loss of function in affected tissues or organs. This increase is primarily fueled by rising environmental pollution, which triggers immune responses and chronic inflammation. C-X-C chemokine receptor type 2 (CXCR2) supports the treatment of these conditions by precisely regulating immune cell migration and inflammatory responses. By enabling small-molecule inhibitors and biologics that specifically modulate CXCR2 activity, it reduces off-target effects, enhances treatment efficacy, and improves patient outcomes. For example, in May 2024, the Centers for Disease Control and Prevention (CDC) reported that the prevalence of asthma among adults aged 18 and over in the United States rose from 8.7% in 2022 to 8.9% in 2023. Thus, the rising prevalence of inflammatory conditions is contributing to the growth of the CXCR2 market.
The growing investments and research and development (R&D) activities are also expected to propel the CXCR2 market forward. Investments involve allocating resources, such as money or assets, to projects or ventures with the expectation of generating future returns, while R&D activities include systematic efforts to innovate technologies, processes, and knowledge to drive growth and competitiveness. Rising investments and R&D are being driven by technological advancements, as companies increasingly allocate resources to innovate, enhance efficiency, and maintain a competitive edge in evolving markets. CXCR2 serves as a promising therapeutic target, encouraging pharmaceutical companies to direct resources toward innovative drug discovery and advanced clinical trials. For instance, in February 2025, the National Science Foundation (NSF) reported that total research and experimental development expenditures in the United States reached $892 billion in 2022 and were estimated to rise to $940 billion in 2023. Therefore, growing investments and R&D activities are fueling the CXCR2 market.
The increasing focus on targeted therapies is also expected to support the growth of the CXCR2 market. Targeted therapies are treatments designed to inhibit specific molecular abnormalities in cancer or other diseases, improving treatment precision while minimizing harm to healthy cells. This trend is primarily driven by advancements in precision medicine, which enable personalized, more effective treatments based on individual genetic profiles. CXCR2 facilitates targeted therapies by guiding immune responses and supporting precise treatment for autoimmune and inflammatory diseases. It contributes to precision medicine by allowing the development of small-molecule inhibitors and biologics that specifically modulate CXCR2 activity, enhancing therapeutic efficacy and reducing off-target effects. For example, in December 2024, the American Society of Gene & Cell Therapy (ASGCT) reported that the FDA approved 6 gene therapy products in 2023, up from 5 in 2022. Thus, the increasing focus on targeted therapies is driving growth in the CXCR2 market.
Major companies operating in the c-x-c chemokine receptor type 2 market are AstraZeneca plc, GSK plc, Eli Lilly and Company, Bio-Techne Corporation, Dompe Farmaceutici S.p.A., Miltenyi Biotec B.V. & Co. KG, Abcam plc, Selleck Chemicals LLC, Cell Signaling Technology Inc., RayBiotech Inc., Bethyl Laboratories Inc., Creative Biolabs Inc., TargetMol LLC, MedChemExpress LLC, BioCompare Inc., Boster Biological Technology Co. Ltd., TME Pharma GmbH, InvivoChem Ltd., Abbexa Ltd., Abiocode Inc.
North America was the largest region in the C-X-C chemokine receptor type 2 market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the c-x-c chemokine receptor type 2 market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the c-x-c chemokine receptor type 2 market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The C-X-C chemokine receptor type 2 market consists of sales of ribonucleic acid (RNA)-based therapeutics, cell-based therapies, biologic response modifiers, diagnostic imaging agents, companion diagnostics, and recombinant proteins. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
C-X-C Chemokine Receptor Type 2 Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses c-x-c chemokine receptor type 2 market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for c-x-c chemokine receptor type 2 ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The c-x-c chemokine receptor type 2 market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.